Montanova Capital Sells $80.4M of Veradermics Stock at $107.25
MANE has more than doubled off its 52-week low of $32.
Summary
Montanova Capital sold $80.4 million of Veradermics stock at $107.25 per share, continuing a wave of insider selling. The funds also exercised 300,000 pre-funded warrants.
Key Events · Ownership and Investor Activity · MANE
-
Insider Sale of $80.4M
Montanova Capital sold 750,000 shares at $107.25 per share on August 19, 2026, for total proceeds of $80,437,500.
-
Warrant Exercise
On August 20, 2026, the funds exercised 300,000 pre-funded warrants at $0.00001 per share, acquiring 300,000 shares of common stock.
-
Continued Insider Selling
This sale follows other insider sales in the past week, including a $15M planned sale by CEO Reid Waldman and a $10.7M sale by Director John W. Childs.
-
Post-Transaction Holdings
After the transactions, the reporting persons hold 3,106,937 shares indirectly.
Analysis · MANE · Life Sciences
Montanova Capital, acting through its funds Averill Master Fund and Averill Madison Master Fund, sold 750,000 shares of Veradermics on August 19 at $107.25 per share, generating $80.4 million. This is a substantial insider sale by a director-affiliated entity, adding to a recent pattern of insider selling. The sale was executed at a price above today's $102.82, but the magnitude and the fact that it follows other insider sales in the past week suggest continued distribution pressure. The funds also exercised 300,000 pre-funded warrants on August 20, acquiring shares at a nominal price, which they may sell in the future.
At the time of this filing, MANE was trading at $102.82 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $32.00 to $131.24. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.